New Hope for Wet AMD Patients: LYTENAVA™ Receives FDA Approval
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in eye care is always met with anticipation. While wet Age-related Macular Degeneration (AMD) is distinct from many inherited retinal diseases, it shares common ground in its impact on central vision and the ongoing need for effective treatments to preserve sight. The recent FDA approval of LYTENAVA™ (bevacizumab-vikg) by Outlook Therapeutics marks a significant milestone in the treatment landscape for wet AMD, offering a new, specifically approved option for a condition that can severely impact daily life.
Wet AMD is a chronic, progressive retinal disease that is a leading cause of severe vision loss among older adults. It occurs when abnormal blood vessels grow under the macula, the part of the retina responsible for sharp, central vision. These fragile vessels can leak fluid or blood, causing damage and rapid vision loss. While wet AMD is not typically classified as an inherited retinal disease in the same way as conditions like Retinitis Pigmentosa or Stargardt disease, genetics can play a role in an individual's risk of developing AMD, and both conditions involve the progressive loss of photoreceptors.
On July 24, 2026, Outlook Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. This approval establishes LYTENAVA™ as the first and only FDA-approved ophthalmic formulation of bevacizumab specifically for wet AMD in the United States. This is particularly noteworthy because, for over two decades, bevacizumab has been widely used in retina care, but without an ophthalmic formulation specifically approved by the FDA for this purpose.
The approval means that retina specialists and patients will now have access to an FDA-approved ophthalmic bevacizumab that has undergone rigorous clinical evaluation, validated manufacturing, and has approved labeling. Outlook Therapeutics anticipates making LYTENAVA™ available to eligible patients in the United States before the end of the year. The company also plans to provide patient access support services, including reimbursement and patient assistance programs, to help integrate LYTENAVA™ into clinical practice.
This development is a testament to ongoing research and dedication in the field of ophthalmology. While wet AMD and IRDs have distinct causes, every advancement in retinal disease treatment brings us closer to a future with more options and improved outcomes for all those affected by vision loss. The availability of an FDA-approved, purpose-built treatment for wet AMD underscores the commitment to addressing critical unmet needs in eye health.